Cyclophilin A: Promising new target in cardiovascular therapy

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2249-2256

  Satoh, Kimio ^a,b   Shimokawa, Hiroaki ^b   Berk, Bradford C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunophilin; Matrix metalloproteinase; Reactive oxygen species; Remodeling; Vasculature

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 6 ANILINO 5,8 QUINOLINEQUINONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHAPERONE; CYCLOPHILIN A; CYCLOSPORIN A; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOPHILIN; MATRIX METALLOPROTEINASE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; RHO KINASE INHIBITOR; SIMVASTATIN; TRANSCRIPTION FACTOR SOX;

ABDOMINAL AORTA ANEURYSM; AORTA RUPTURE; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CELL GROWTH; DRUG TARGETING; ENZYME ACTIVATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOXIA; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TRANSPORT; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CYCLOPHILIN A; ENZYME ACTIVATION; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR CHAPERONES; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 78449257436     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0904     Document Type: Review

References (104)

1. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J Mol Cell Cardiol 1999; 31: 23-37.
2. Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Araki H, Nakamura M, et al. Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983; 221: 560-562.
3. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: A new activity for platelet-derived growth factor. Science 1986; 232: 87-90.
4. Griendling KK, Berk BC, Ganz P, Gimbrone MA Jr, Alexander RW. Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism [State of the art lecture]. Hypertension 1987; 9: III181-III185.
5. Berk BC. Vascular smooth muscle growth: Autocrine growth mechanisms. Physiol Rev 2001; 81: 999-1030.
6. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension 2003; 42: 1075-1081.
7. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med 1998; 132: 9-15.
8. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-547.
9. Harding MW, Handschumacher RE, Speicher DW. Isolation and amino acid sequence of cyclophilin. J Biol Chem 1986; 261: 8547-8555.
10. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidylprolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755-757.
11. Bierer BE, Cyclosporin A, FK506, and rapamycin: Binding to immunophilins and biological action. Chem Immunol 1994; 59: 128-155.
12. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996; 76: 631-649.
13. Galat A, Metcalfe SM. Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol 1995; 63: 67-118.
14. Ryffel B, Woerly G, Greiner B, Haendler B, Mihatsch MJ, Foxwell BM. Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology 1991; 72: 399-404.
15. Marks WH, Harding MW, Handschumacher R, Marks C, Lorber MI. The immunochemical distribution of cyclophilin in normal mammalian tissues. Transplantation 1991; 52: 340-345.
16. Sarris AH, Harding MW, Jiang TR, Aftab D, Handschumacher RE. Immunofluorescent localization and immunochemical determination of cyclophilin-A with specific rabbit antisera. Transplantation 1992; 54: 904-910.
17. Uittenbogaard A, Ying Y, Smart EJ. Characterization of a cytosolic heat-shock protein-caveolin chaperone complex: Involvement in cholesterol trafficking. J Biol Chem 1998; 273: 6525-6532.
18. Steinmann B, Bruckner P, Superti-Furga A. Cyclosporin A slows collagen triple-helix formation in vivo: Indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase. J Biol Chem 1991; 266: 1299-1303.
19. Zhu C, Wang X, Deinum J, Huang Z, Gao J, Modjtahedi N, et al. Cyclophilin A participates in the nuclear translocation of apoptosis apoptosis- inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med 2007; 204: 1741-1748.
20. Krummrei U, Bang R, Schmidtchen R, Brune K, Bang H. Cyclophilin-A is a zinc-dependent DNA binding protein in macrophages. FEBS Lett 1995; 371: 47-51.
21. Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT. Human cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci USA 1991; 88: 1903-1907.
22. Schneider H, Charara N, Schmitz R, Wehrli S, Mikol V, Zurini MG, et al. Human cyclophilin C: Primary structure, tissue distribution, and determination of binding specificity for cyclosporins. Biochemistry 1994; 33: 8218-8224.
23. Bergsma DJ, Eder C, Gross M, Kersten H, Sylvester D, Appelbaum E, et al. The cyclophilin multigene family of peptidylprolyl isomerases: Characterization of three separate human isoforms. J Biol Chem 1991; 266: 23204-23214.
24. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-662.
25. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008; 14: 1097-1105.
26. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: A mechanistic linkage by cyclophilin A. Antioxid Redox Signal 2010; 12: 675-682.
27. RW. Hypertension and the pathogenesis of atherosclerosis: Oxidative stress and the mediation of arterial inflammatory response: A new perspective [Theodore Cooper Memorial Lecture]. Hypertension 1995; 25: 155-161.
28. Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS. Inhibition of coronary artery superoxide dismutase attenuates endothelium- dependent and -independent nitrovasodilator relaxation. Circ Res 1991; 69: 601-608.
29. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H2O2 and O2- in vascular smooth muscle cells. Circ Res 1995; 77: 29-36.
30. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000; 106: 1521-1530.
31. Takaki A, Morikawa K, Tsutsui M, Murayama Y, Tekes E, Yamagishi H, et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008; 205: 2053-2063.
32. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 2006; 71: 216-225.
33. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
34. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70: 593-599.
35. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-196.
36. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000; 87: 789-796.
37. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 1186-1191.
38. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 2006; 98: 811-817.
39. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61: 2276-2281.
40. Pushkarsky T, Zybarth G, Dubrovsky L, Yurchenko V, Tang H, Guo H, et al. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci USA 2001; 98: 6360-6365.
41. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006; 69: 614-624.
42. Mackay DJ, Hall A. Rho GTPases. J Biol Chem 1998; 273: 20685-20688.
43. Neco P, Giner D, Viniegra S, Borges R, Villarroel A, Gutierrez LM. New roles of myosin II during vesicle transport and fusion in chromaffin cells. J Biol Chem 2004; 279: 27450-27457.
44. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273: 245-248.
45. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009; 15: 649-656.
46. Griendling KK, Fitz Gerald GA. Oxidative stress and cardiovascular injury. Part II: Animal and human studies. Circulation 2003; 108: 2034-2040.
47. Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1332-1340.
48. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-S420.
49. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
50. Li M, Fukagawa NK. Age-related changes in redox signaling and VSMC function. Antioxid Redox Signal 2010; 12: 641-655.
51. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009; 73: 615-621.
52. Kim H, Kim WJ, Jeon ST, Koh EM, Cha HS, Ahn KS, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol 2005; 116: 217-224.
53. Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol 2007; 82: 613-618.
54. Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxf) 2008; 47: 1299-1310.
55. Wang L, Wang CH, Jia JF, Ma XK, Li Y, Zhu HB, et al. Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis. J Clin Immunol 2010; 30: 24-33.
56. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008; 117: 3088-3098.
57. Jin ZG, Berk BC. SOXF: Redox mediators of vascular smooth muscle cell growth. Heart 2004; 90: 488-490.
58. Payeli SK, Schiene-Fischer C, Steffel J, Camici GG, Rozenberg I, Luscher TF, et al. Cyclophilin A differentially activates monocytes and endothelial cells: Role of purity, activity, and endotoxin contamination in commercial preparations. Atherosclerosis 2008; 197: 564-571.
59. Khromykh LM, Kulikova NL, Anfalova TV, Muranova TA, Abramov VM, Vasiliev AM, et al. Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol 2007; 249: 46-53.
60. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-1612.
61. Daugherty A, Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 2004; 14: 117-120.
62. Thomas M, Gavrila D, McCormick ML, Miller FJ Jr, Daugherty A, Cassis LA, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006; 114: 404-413.
63. Gavazzi G, Deffert C, Trocme C, Schappi M, Herrmann FR, Krause KH. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 2007; 50: 189-196.
64. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999; 878: 159-178.
65. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-488.
66. Cassis LA, Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 2007; 27: 380-386.
67. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.
68. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213-220.
69. Kunieda T, Minamino T, Nishi J, Tateno K, Oyama T, Katsuno T, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 2006; 114: 953-960.
70. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003; 112: 1318-1331.
71. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11: 1330-1338.
72. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117: 3359-3368.
73. Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
74. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
75. Nigro P, Abe JI, Woo CH, Satoh K, McClain C, O'Dell MR, et al. PKC? decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood 2010 [Epub ahead of print].
76. Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, et al. Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest 2003; 112: 1871-1879.
77. Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J 2009; 73: 394-403.
78. Satoh K, O'Dell MR, Liao DF, Cui Z, Nigro P, Mohan A, et al. Cyclophilin A is a novel proinflammatory cytokine that accelerates development of atherosclerosis. Circulation 2008; 118: S309-S310.
79. Nigro P, Satoh K, O'Dell MR, Soe N, Cui Z, Mohan A, et al. Cyclophilin A mediates endothelial damage and promotes recruitment of inflammatory cells and atherosclerosis. Circulation 2009; 120: S1096-S1097.
80. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97.
81. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984.
82. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98: 794-799.
83. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM. NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 2009; 47: 15-22.
84. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73: 608-614.
85. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241-248.
86. Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; 100: 2279-2288.
87. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-1450.
88. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100: 662-669.
89. Doe Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1731-1739.
90. Satoh K, Fukumoto Y, Sugimura K, Tatebe S, Miura Y, Miyamichi S, et al. Cyclophilin A mediates pulmonary vascular remodeling by rho-kinase activation in patients with pulmonary hypertension. Circulation 2010; 122 (Suppl): (in press).
91. Hayashida K, Fujita J, Miyake Y, Kawada H, Ando K, Ogawa S, et al. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest 2005; 127: 1793-1798.
92. Satoh K, Berk BC. Circulating smooth muscle progenitor cells: Novel players in plaque stability. Cardiovasc Res 2008; 77: 445-447.
93. Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, et al. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009; 81: 226-234.
94. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393.
95. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, et al. C-type natriuretic peptide ameliorates monocrotalineinduced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 170: 1204-1211.
96. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
97. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 2005; 111: 2219-2226.
98. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-775.
99. Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S, et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: Protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003; 59: 988-996.
100. Guo H, Majmudar G, Jensen TC, Biswas C, Toole BP, Gordon MK. Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene 1998; 220: 99-108.
101. Haug C, Lenz C, Diaz F, Bachem MG. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase Inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 1823-1829.
102. Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T, et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277: 22959-22965.
103. Chen XF, Wang JA, Hou J, Gui C, Tang LJ, Chen XQ, et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) is present in smooth muscle cells of human aneurysmal aorta and is induced by angiotensin II in vitro. Clin Sci (Lond) 2009; 116: 819-826.
104. Venkatesan B, Valente AJ, Prabhu SD, Shanmugam P, Delafontaine P, Chandrasekar B. EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB and MKK7/JNK/AP-1 signaling. J Mol Cell Cardiol 2010; 49: 655-663.